Institute for Clinical and Economic Review publishes evidence report on treatment for post-traumatic stress disorder

14 May 2024 - There are substantial uncertainties around the clinical trial results; given the inability to assess net benefit, ...

Read more →

ICER publishes final evidence report on treatments for paroxysmal nocturnal haemoglobinuria

13 March 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate a net health benefit ...

Read more →

ICER publishes final evidence report on treatment for schizophrenia

11 March 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits ...

Read more →

ICER publishes evidence report on treatments for paroxysmal nocturnal haemoglobinuria

1 February 2024 - Iptacopan and danicopan are two first in class agents that provide important health benefits, but there ...

Read more →

ICER publishes evidence report on treatment for schizophrenia

25 January 2024 - KarXT has a novel mechanism of action, but there are significant uncertainties regarding long term efficacy ...

Read more →

ICER publishes final evidence report on treatment for pulmonary arterial hypertension

8 January 2024 - Independent appraisal committee voted that sotatercept demonstrated a net health benefit when compared to background therapy; ...

Read more →

ICER publishes final evidence report on gene therapy for metachromatic leukodystrophy

30 October 2023 - Independent appraisal committee voted that across all patient sub-populations, arsa-cel demonstrated a net health benefit when ...

Read more →

ICER publishes final evidence report on gene therapies for sickle cell disease

21 August 2023 - Current evidence suggests that lovo-cel and exa-cel would achieve common thresholds for cost-effectiveness if priced between $1.35 ...

Read more →

ICER publishes final evidence report on treatments for non-alcoholic steatohepatitis

25 May 2023 - Independent appraisal committee narrowly voted that currently available evidence for resmetirom is adequate to demonstrate a net ...

Read more →

ICER publishes evidence report on gene therapies for haemophilia A and B

2 November 2022 - Duration of benefit with gene therapies and risks for rare side effects remain major uncertainties. ...

Read more →

ICER publishes final evidence report and policy recommendations on treatments for obesity management

20 October 2022 - Independent appraisal committee voted that evidence is adequate to demonstrate that semaglutide provides a net health benefit ...

Read more →

ICER publishes final evidence report and policy recommendations on treatments for amyotrophic lateral sclerosis

13 September 2022 - Majority of independent appraisal committee voted that evidence is adequate to demonstrate that both AMX0035 and oral ...

Read more →

ICER publishes final evidence report and policy recommendations on beti-cel gene therapy for beta thalassaemia

19 July 2022 - Independent appraisal committee unanimously determined that evidence is adequate to demonstrate that beti-cel provides a net ...

Read more →

ICER publishes final evidence report and policy recommendations on outpatient treatments for COVID-19

10 May 2022 - Independent appraisal committee votes 11-2 that the evidence is not adequate to demonstrate a net health benefit ...

Read more →

ICER publishes final evidence report and policy recommendations on tirzepatide for type 2 diabetes

15 February 2022 - Independent appraisal committee found that evidence is adequate to demonstrate a net health benefit of tirzepatide added ...

Read more →